1016686-46-6

Basic information

• Product Name: 5-(5-chloro-2-methoxyphenyl)-1,3,4-oxadiazol-2-amine
• Synonyms: 5-(5-chloro-2-methoxyphenyl)-1,3,4-oxadiazol-2-amine
• CAS NO: 1016686-46-6
• Molecular Formula: C9H8ClN3O2
• Molecular Weight: 225.63172
• Mol File: 1016686-46-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(5-chloro-2-methoxyphenyl)-1,3,4-oxadiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(5-chloro-2-methoxyphenyl)-1,3,4-oxadiazol-2-amine(1016686-46-6)
• EPA Substance Registry System: 5-(5-chloro-2-methoxyphenyl)-1,3,4-oxadiazol-2-amine(1016686-46-6)

Safety Data

• Hazardous Substances Data: 1016686-46-6(Hazardous Substances Data)

Upstream product

• 7035-09-8 5-chloro-2-methoxybenzaldehyde 

Relevant articles and documents

Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence in Vivo

Clostridioides difficile is the leading cause of healthcare-associated infection in the U.S. and considered an urgent threat by the Centers for Disease Control and Prevention (CDC). Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. difficile infection (CDI), but these therapies still suffer from high treatment failure and recurrence. Therefore, new chemical entities to treat CDI are needed. Trifluoromethylthio-containing N-(1,3,4-oxadiazol-2-yl)benzamides displayed very potent activities [sub-μg/mL minimum inhibitory concentration (MIC) values] against Gram-positive bacteria. Here, we report remarkable antibacterial activity enhancement via halogen substitutions, which afforded new anti-C. difficile agents with ultrapotent activities [MICs as low as 0.003 μg/mL (0.007 μM)] that surpassed the activity of vancomycin against C. difficile clinical isolates. The most promising compound in the series, HSGN-218, is nontoxic to mammalian colon cells and is gut-restrictive. In addition, HSGN-218 protected mice from CDI recurrence. Not only does this work provide a potential clinical lead for the development of C. difficile therapeutics but also highlights dramatic drug potency enhancement via halogen substitution.